These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11021187)

  • 21. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of combination therapy with a calcium channel blocker and an angiotensin-converting enzyme inhibitor on renal hypertrophy and urinary albumin excretion in diabetic rats.
    Nielsen B; Grønbaek H; Osterby R; Flyvbjerg A
    Exp Diabesity Res; 2003; 4(3):191-9. PubMed ID: 15061647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of trandolapril, in monotherapy and associated with verapamil, on arterial pressure, albuminuria, and metabolic control in hypertensive patients with type 2 diabetes and albuminuria].
    Fernández González R; García Robles R; Rodríguez Pérez JC; Gómez Pajuelo C; Moreno Carretero E;
    Nefrologia; 2001; 21(5):456-63. PubMed ID: 11795014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function].
    Iakusevich VV; Mozheĭko ME; Paliutin ShKh; Berezina MIu; Martsevich SIu; Shal'nova SA; Deev AD; Kutishenko NP; Alimova EV; Koniakhina IP; Semenova IuE
    Ter Arkh; 2000; 72(10):82-6. PubMed ID: 11220887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
    Bakris GL; Williams B
    J Hypertens Suppl; 1995 Aug; 13(2):S95-101. PubMed ID: 8576797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
    Faller J; Hess B
    Praxis (Bern 1994); 2002 May; 91(19):836-44. PubMed ID: 12071084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?
    Jespersen CM
    Cardiologia; 1995 Dec; 40(12 Suppl 1):307-10. PubMed ID: 8903054
    [No Abstract]   [Full Text] [Related]  

  • 34. [Sulodexid and nephrotic syndrome in patients with diabetic nephropathy].
    Valociková I
    Vnitr Lek; 2011 May; 57(5):507-10. PubMed ID: 21695933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy.
    Cucak H; Nielsen Fink L; Højgaard Pedersen M; Rosendahl A
    Int Immunopharmacol; 2015 Mar; 25(1):30-42. PubMed ID: 25598292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin.
    Martínez-Castelao A; Hueso M; Sanz V; Rejas J; Alsina J; Grinyó JM
    Kidney Int Suppl; 1998 Dec; 68():S130-4. PubMed ID: 9839297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study.
    Boero R; Rollino C; Massara C; Berto IM; Perosa P; Vagelli G; Lanfranco G; Quarello F
    Am J Kidney Dis; 2003 Jul; 42(1):67-75. PubMed ID: 12830458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor.
    McGregor D; Bailey RR
    Nephron; 1997; 76(3):270-5. PubMed ID: 9226226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin converting enzyme inhibitor induced anemia in a kidney transplant recipient.
    Kuriyama R; Kogure H; Itoh S; Kikuchi K; Ichikawa N; Nomura Y; Degawa H; Meigata K; Watanabe K; Beck Y; Tomikawa S; Nagao T; Uchida H
    Transplant Proc; 1996 Jun; 28(3):1635. PubMed ID: 8658817
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of camostat mesilate on urinary protein excretion in three patients with advanced diabetic nephropathy.
    Ikeda Y; Ito H; Hashimoto K
    J Diabetes Complications; 1999; 13(1):56-8. PubMed ID: 10232711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.